Extending transdermal nicotine therapy from 8 to 24 weeks increases point-prevalence abstinence at 24 but not 52 weeks
- PMID: 20522690
- DOI: 10.1136/ebm1064
Extending transdermal nicotine therapy from 8 to 24 weeks increases point-prevalence abstinence at 24 but not 52 weeks
Comment on
-
Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial.Ann Intern Med. 2010 Feb 2;152(3):144-51. doi: 10.7326/0003-4819-152-3-201002020-00005. Ann Intern Med. 2010. PMID: 20124230 Free PMC article. Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources